<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04567693</url>
  </required_header>
  <id_info>
    <org_study_id>2020-11551</org_study_id>
    <secondary_id>K23MH114752</secondary_id>
    <nct_id>NCT04567693</nct_id>
  </id_info>
  <brief_title>Reducing Time to Spaced-out Appointments for Newly-diagnosed People Living With HIV</brief_title>
  <official_title>Reducing Time to Spaced-out Appointments for Newly-diagnosed People Living With HIV: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rwanda Military Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to pilot test the effect of reducing time to spaced-out&#xD;
      appointments from 18 to 6 months for newly-diagnosed people living with HIV (PLWH) in Rwanda&#xD;
      who have initiated antiretroviral therapy (ART). PLWH are currently required to visit the&#xD;
      health center monthly for ART and clinical appointments for the first 18 months on ART, after&#xD;
      which they can attend quarterly. Reducing the time to spaced-out appointments from 18 to 6&#xD;
      months has the potential to reduce the burden on patients and the health system, but may lead&#xD;
      to suboptimal treatment outcomes. To better understand the effects of early spaced-out&#xD;
      appointments as well as the degree of viral load monitoring needed to determine stability on&#xD;
      ART, the investigators will conduct a 3-arm pilot intervention study. The investigators will&#xD;
      randomize participants to 1) 6-month advancement to spaced-out appointments after 1 viral&#xD;
      load measurement; 2) 6-month advancement to spaced-out appointments after 2 viral load&#xD;
      measurements; or 3) usual care. The investigators will compare the study arms with respect to&#xD;
      viral suppression at 12 months after enrollment in ART care (primary outcome) and&#xD;
      appointment/ pharmacy adherence (secondary outcome).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Most countries in sub-Saharan Africa have adopted differentiated care models for people&#xD;
      living with HIV (PLWH), including Rwanda. Current Rwandan HIV guidelines classify&#xD;
      newly-diagnosed PLWH as &quot;unstable&quot;, requiring monthly visits to the health facility. Before&#xD;
      they can advance to being &quot;stable&quot; patients, with spaced-out appointments that allow them to&#xD;
      visit the health facility every three months, they must be on antiretroviral therapy (ART)&#xD;
      for 18 months and virally suppressed on two consecutive measurements. Patients face multiple&#xD;
      barriers to attending frequent appointments including structural issues (such as distance to&#xD;
      the health facility, transportation cost, long waiting times) and facing stigma while&#xD;
      traveling to and while at the health facility. Reducing the time newly-diagnosed PLWH spend&#xD;
      in the &quot;unstable&quot; category could potentially decrease the burden on patients and the health&#xD;
      facility and potentially decrease the costs of frequent appointments. The investigators&#xD;
      therefore propose a pilot study to examine the effect of reducing the time from ART&#xD;
      initiation to advancement to the &quot;stable&quot; category from 18 to 6 months. The investigators&#xD;
      will enroll 90 patients: 30 will be randomized to 6-month advancement to spaced out&#xD;
      appointments after 1 viral load is measured (at 5 months after enrollment in ART care)&#xD;
      (&quot;Early 1&quot;); 30 will be randomized to 6-month advancement to spaced-out appointments after 2&#xD;
      viral loads are measured (at 3- and 5-months after enrollment in ART care) (&quot;Early 2&quot;); and&#xD;
      30 will be randomized to continue in usual care with monthly visits (&quot;Usual care&quot;). The&#xD;
      investigators will compare study arms with respect to viral suppression at 12 months (primary&#xD;
      outcome) and appointment/pharmacy adherence (secondary outcome). The investigators&#xD;
      hypothesize that reducing the time to the &quot;stable&quot; category with spaced out appointments will&#xD;
      be feasible, acceptable, not inferior to 18 months with respect to viral suppression or&#xD;
      adherence, and will be cost-effective.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 22, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viral suppression</measure>
    <time_frame>Measured at 12 months after enrollment into ART care</time_frame>
    <description>Proportion of participants with suppressed viral load (less than 200 copies/ml)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Appointment adherence</measure>
    <time_frame>Measured at 12 months after enrollment into ART care</time_frame>
    <description>Proportion of participants that attended all pharmacy and clinical appointments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant acceptability of reduced time to spaced-out appointments</measure>
    <time_frame>Measured at 12 months after enrollment into ART care</time_frame>
    <description>Acceptability of reduced time to spaced-out appointments, as measured by interview responses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Provider acceptability of reduced time to spaced-out appointments</measure>
    <time_frame>Measured at 12 months after enrollment into ART care</time_frame>
    <description>Acceptability of reduced time to spaced-out appointments, as measured by interview responses</description>
  </secondary_outcome>
  <other_outcome>
    <measure>ART adherence</measure>
    <time_frame>Measured at 1-, 6- and 12-months after enrollment in ART care</time_frame>
    <description>Repeated measures analysis of patient self-reported ART adherence</description>
  </other_outcome>
  <other_outcome>
    <measure>Perceived quality of life assessed by the EQ-5D-5L</measure>
    <time_frame>Measured at 1-, 6- and 12-months after enrollment in ART care</time_frame>
    <description>Repeated measures analysis of participant quality of life as measured by the EuroQOL-5 Dimension-5 Levels (EQ-5D-5L). The EQ-5D-5L is a 5-level scale that measures self-rated problems (no problems, slight problems, moderate problems, severe problems and extreme problems) in 5 domains (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) as well as self-rated health. Each domain is scored from 1 (no problems) to 5 (extreme problems); the overall health state is described by a 5-digit number defined by combining one level from each dimension, ranging from 11111 (full health) to 55555 (worst health).</description>
  </other_outcome>
  <other_outcome>
    <measure>Satisfaction with care assessed by scales developed by Lannes, et al. and Parcescepe, et al.</measure>
    <time_frame>Measured at 1-, 6- and 12-months after enrollment in ART care</time_frame>
    <description>Repeated measures analysis of participant satisfaction with health care received as measured by scales developed by Lannes, et al. and Parcescepe, et al. The Lannes scale is a 5-level scale (very satisfied, satisfied, no opinion, not satisfied, very unsatisfied) that asks participants to describe satisfaction with several elements of receiving health care. The Parcescepe, et al scale is a 2-level scale (agree, disagree) that asks participants to agree or disagree with various aspects of care received at the health center.</description>
  </other_outcome>
  <other_outcome>
    <measure>Enacted stigma assessed by the HASI-P scale</measure>
    <time_frame>Measured at 1-, 6- and 12-months after enrollment in ART care</time_frame>
    <description>Repeated measures analysis of enacted stigma in community and health care settings as measured by the HIV/AIDS Stigma Instrument-PLWA (HASI-P) Scale. The HASI-P is a 33-item scale that contains questions in 6 different stigma-related domains or factors. For each item, participants are asked to describe the frequency of experienced stigmatizing events in the past 3 months on a 4-point Likert scale (0- Never, 1- Once or twice, 2- Several times, or 3- Most of the time). The instrument is scored by summing the scores (0-3) for each item and then dividing by the number of items within each factor. Higher scores are interpreted as reflecting greater levels of received or associated stigma.</description>
  </other_outcome>
  <other_outcome>
    <measure>Internalized, anticipated and enacted stigma assessed by the HIV stigma scale</measure>
    <time_frame>Measured at 1-, 6- and 12-months after enrollment in ART care</time_frame>
    <description>Repeated measures analysis of internalized, anticipated and enacted stigma as measured by an adapted version of the HIV stigma scale. Items are rated on 5-point Likert-type scales (Internalized: ranging from Strongly Disagree [1] to Strongly Agree [5]; Anticipated: ranging from Very Unlikely [1] to Very Likely [5]; Enacted: ranging from Never [1] to Very Often [5]) with higher scores indicating greater stigma. Items are averaged to create composite scores, subdivided by type of stigma (internalized, anticipated or enacted).</description>
  </other_outcome>
  <other_outcome>
    <measure>Participant health-related costs</measure>
    <time_frame>Measured at 1-, 6- and 12-months after enrollment in ART care</time_frame>
    <description>Repeated measures analysis of participant direct and indirect costs</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Hiv</condition>
  <condition>Aids</condition>
  <arm_group>
    <arm_group_label>Early 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advance to spaced-out appointments at month 6 after a single viral load is measured.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Early 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advance to spaced-out appointments at month 6 after two viral loads are measured.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Do not advance to spaced-out appointments during study period</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Early spaced-out appointments</intervention_name>
    <description>Newly-diagnosed PLWH currently attend health centers monthly for ART pick-up and quarterly for clinical visits. In the intervention arms, participants will attend health centers quarterly for ART pick-up and semi-annually for clinical visits.</description>
    <arm_group_label>Early 1</arm_group_label>
    <arm_group_label>Early 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. â‰¥15 years;&#xD;
&#xD;
          2. newly-diagnosed with HIV (within 6 months);&#xD;
&#xD;
          3. enrolled in care at study health facility;&#xD;
&#xD;
          4. initiated ART.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. planning on moving away from health center/Kigali in the next 12 months;&#xD;
&#xD;
          2. unable to provide informed consent;&#xD;
&#xD;
          3. enrolled in care while pregnant;&#xD;
&#xD;
          4. co-infected with tuberculosis;&#xD;
&#xD;
          5. concurrent known mental health or substance use disorder.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Ross</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rwanda Military Hospital</name>
      <address>
        <city>Kigali</city>
        <country>Rwanda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Rwanda</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 17, 2020</study_first_submitted>
  <study_first_submitted_qc>September 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2020</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Jonathan Ross</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Rwanda</keyword>
  <keyword>Treat All</keyword>
  <keyword>Antiretroviral therapy</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>As this is a pilot study, we have elected to not allow for data to be available to other researchers for secondary analyses.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT04567693/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

